Related Experiment Video
Updated: May 9, 2026
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Published on: June 28, 2013
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Alexios S Strimpakos1, Muhammad Wasif Saif
1Division of Oncology, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece.
Abstract:
Over the last twenty years, there is a limited number of effective cytotoxic or biological agents that managed to get approval in advanced pancreatic ductal adenocarcinoma. Despite numerous trials, investments in translational research and generally in health care, the survival of pancreatic cancer patients has improved by a few only months. This disappointing reality necessitates a better understanding of the pathogenesis of this disease and the identification of targetable alterations which might lead to development of more effective drugs or better combinations. At the 2013 Annual Meeting of the American Society of Clinical Oncology, few novel agents and new therapeutic concepts, tested in phase I studies in advanced pancreatic ductal adenocarcinoma, were presented. The first notable phase I study referred to the combination of chemotherapy with local delivery of silencing RNA against the K-ras mutation G12D, in advanced pancreatic ductal adenocarcinoma, which was well tolerated and promising (Abstract #4037). The second one referred to a combination of gemcitabine with pegylated recombinant human hyaluronidase (PEGPH20), an inhibitor of hyaluronan which as a matrix glycosaminoglycan is believed to play role in the reduced drug delivery to cancer (Abstract #4010). The other notable abstract was related to an early phase study which tested the safety and toxicity of arctigenin, a traditional herbal agent found in Arctium lappa Linné, administered as an oral formulation (GMS-01) in pancreatic ductal adenocarcinoma patient resistant to standard chemotherapy (Abstract #2559). The aforementioned early phase studies open new therapeutic approaches which deserve further testing in advanced pancreatic cancer.
Insights
Novel therapies show promise for advanced pancreatic cancer. Early phase studies explore RNA silencing for K-ras mutations, hyaluronidase to improve drug delivery, and arctigenin for chemotherapy-resistant cases.
Area of Science:
- Oncology
- Translational Research
- Drug Development
Background:
- Advanced pancreatic ductal adenocarcinoma has limited effective treatment options, with minimal survival improvements over two decades.
- Despite research investment, patient survival remains poor, highlighting the need for better understanding and targeted therapies.
- Identifying new therapeutic targets and drug combinations is crucial for improving outcomes in pancreatic cancer.
Purpose of the Study:
- To present novel therapeutic agents and concepts for advanced pancreatic ductal adenocarcinoma from early phase studies.
- To highlight promising new treatment strategies tested at the 2013 American Society of Clinical Oncology Annual Meeting.
- To identify potential new avenues for treating pancreatic cancer patients with limited options.
Main Methods:
- Phase I studies evaluating safety, tolerability, and preliminary efficacy of novel agents.
- Combination therapy including chemotherapy with RNA silencing targeting K-ras G12D mutation.
- Investigating pegylated recombinant human hyaluronidase (PEGPH20) with gemcitabine to overcome drug delivery barriers.
- Assessing the safety and toxicity of oral arctigenin in patients resistant to standard chemotherapy.
Main Results:
- Combination of chemotherapy with K-ras G12D silencing RNA was well-tolerated and showed promise.
- Gemcitabine combined with PEGPH20 demonstrated potential in addressing drug delivery challenges.
- Arctigenin (GMS-01) showed acceptable safety and toxicity profiles in a phase I study for resistant pancreatic cancer.
- Early phase studies indicate these novel approaches warrant further investigation.
Conclusions:
- Novel therapeutic strategies, including RNA silencing, hyaluronidase, and arctigenin, offer new hope for advanced pancreatic cancer.
- These early phase findings suggest potential for improved treatment efficacy and patient outcomes.
- Further clinical trials are necessary to validate the effectiveness of these promising agents in pancreatic ductal adenocarcinoma.
